Arrowhead to present 12-month SHASTA-3/SHASTA-4 data at ESC 2026, keeping sHTG timeline on track

What happened

Arrowhead announced it will present 12-month data from the pivotal SHASTA-3 and SHASTA-4 trials of plozasiran in severe hypertriglyceridemia at the European Society of Cardiology Congress on August 30, 2026. The presentation is scheduled as a Hot Line late-breaking session, which is typical for high-profile cardiovascular data. This confirms the company's prior guidance that sHTG Phase 3 top-line results would be available in Q3 2026. However, the announcement itself contains no efficacy or safety data; it only signals the timing and venue. Investors must wait for the actual presentation to assess whether the data support an sNDA filing by year-end 2026.

Implication

For investors, this announcement reinforces the near-term catalyst calendar: the ESC presentation on August 30, 2026 serves as the de facto top-line readout for the sHTG program and will likely drive a sharp re-rating if data are positive, consistent with the base and bull scenarios. Conversely, if the data disappoint, the stock could fall toward the bear-case value of $40, given the current valuation already discounts successful expansion. The master report's WAIT rating remains appropriate because the key binary event is now less than a week away, and the risk/reward does not favor adding ahead of the data. After the data, investors should reassess REDEMPLO launch traction and the fixed-cost build, as the next 90 days will clarify whether the company can transition to sustainable product sales.

Thesis delta

The announcement aligns with the company's stated timeline for sHTG Phase 3 top-line data in Q3 2026, but it does not change the fundamental valuation bridge, which still depends on both successful data and REDEMPLO commercial execution. The master report's WAIT rating remains unchanged; the catalyst is now imminent but still unproven. Confidence in the timeline increases slightly, but the core risk of data disappointment and commercialization lag persists.